mTOR inhibition for generating memory T cells to enhance ovarian tumor immunity

描述（由申请人提供）：我们研究的目标是产生持久的CD 8 + T细胞应答，以对抗上皮性卵巢癌（EOC），从而延长缓解率。然而，存在开发有效免疫疗法的主要障碍，包括（i）不能诱导高亲合力肿瘤抗原特异性效应CD 8 + T细胞的扩增，（ii）缺乏肿瘤抗原特异性记忆CD 8 + T细胞，和（iii）存在CD 4 + CD 25 + FOXP 3+调节性T细胞。在以前的研究中，我们已经观察到，虽然疫苗诱导的肿瘤抗原特异性效应CD 8 + T细胞可以提供肿瘤保护，但它们不提供持久的肿瘤免疫，这通常由记忆T细胞提供。我们还注意到雷帕霉素介导的哺乳动物雷帕霉素靶蛋白（mTOR）的抑制通过调节转录因子T-bet和Eomesodermin将效应CD 8 + T细胞转换为记忆。此外，在我们的鼠模型中，免疫后改变mTOR抑制的持续时间（0-8、0-20或0-40天）产生具有不同程度的1型效应子功能的记忆CD 8 + T细胞。因此，我们假设，通过改变免疫卵巢癌患者的雷帕霉素给药方案（剂量和持续时间），我们将产生具有不同程度效应功能的高亲和力CD 8 + T细胞，以获得持久的卵巢肿瘤免疫力。因此，我们的目标是确定mTOR抑制的方案，其与病毒载体免疫结合不产生毒性，但在I期临床试验中产生最佳持久的CD 8 + T细胞应答。其次，通过改变雷帕霉素给药的时间，我们将确定mTOR抑制产生功能不同的高亲和力记忆性CD 8 + T细胞的机制。为了检验我们的假设，我们提出：SA 1：确定mTOR抑制方案（剂量和持续时间），其与rCNP-NY-ESO-1/TRICOM免疫联合使用是安全的，并在I期临床试验中产生持久的CD 8 + T细胞应答。SA2：测试rCNP-NY-ESO-1/TRICOM免疫后雷帕霉素施用方案是否产生具有不同程度的效应子功能和抗原亲合力的记忆性CD 8 + T细胞。SA 3：确定雷帕霉素处理方案对rCNP-NY-ESO-1/TRICOM诱导的CD 4 + T细胞应答对CD 8 + T细胞记忆生成的影响。我们提出的研究的成功完成将产生关键数据，这些数据将促进mTOR抑制的II期评价，以产生高亲和力记忆T细胞，促进有利于持久宿主免疫的条件，并延长卵巢癌患者的无病生存期。

DESCRIPTION (provided by applicant): The goal of our studies is to generate durable CD8+ T cell responses against epithelial ovarian cancer (EOC) for extending remission rates. However, major obstacles to the development of effective immunotherapy exist including (i) inability to induce expansion of high avidity, tumor-antigen specific effector CD8+ T cells (ii) lack of tumor-antigen specific memory CD8+ T cells, and (iii) presence of CD4+CD25+FOXP3+ regulatory T cells. In previous studies, we have observed that although vaccine induced tumor antigen specific effector CD8+ T cells can provide tumor protection, they do not provide durable tumor immunity, which is typically afforded by memory T cells. We have also noted that rapamycin mediated inhibition of mammalian target of rapamycin (mTOR) switches effector CD8+ T cells to memory via regulation of transcriptional factors T-bet and Eomesodermin. Moreover, in our murine model, varying the duration (0-8, 0-20 or 0-40 days) of mTOR inhibition after immunization produces memory CD8+ T cells with varying extent of type 1 effector functions. Consequently, we hypothesize that by changing the regimen (dose and duration) of rapamycin administration in immunized ovarian cancer patients, we will generate high avidity CD8+ T cells with varying extent of effector functions for durable ovarian tumor immunity. Therefore, our objectives are to determine the regimen of mTOR inhibition, that in combination with viral vector immunization does not produce toxicity but generates optimal durable CD8+ T cell responses in a phase I clinical trial. Second, by varying the timing of rapamycin administration, we will determine the mechanisms by which mTOR inhibition produces functionally distinct memory CD8+ T cells of high avidity. To test our hypotheses, we propose: SA1: To determine the regimen (dose and duration) of mTOR inhibition that in combination with rCNP-NY-ESO-1/TRICOM immunization is safe and produces durable CD8+ T cell responses in a phase I clinical trial. SA2: To test whether the regimen of rapamycin administration after rCNP-NY-ESO-1/TRICOM immunization generates memory CD8+ T cells with varying extent of effector functions and antigen avidity. SA3: To determine the impact of rapamycin treatment regime on rCNP-NY-ESO-1/TRICOM induced CD4+ T cell response for CD8+ T cell memory generation. The successful completion of our proposed studies will result in the generation of critical data that will facilitate Phase II evaluation of mTOR inhibition to generate high avidity memory T cells, promote conditions that favor durable host immunity, and prolong disease free survival in ovarian cancer patients.